1267PTopline results from phase II of combination treatment with canerpaturev (HF10), an oncolytic viral immunotherapy, and ipilimumab in patients with unresectable or metastatic melanoma after anti-PD-1 therapy

@inproceedings{Isei20181267PToplineRF,
  title={1267PTopline results from phase II of combination treatment with canerpaturev (HF10), an oncolytic viral immunotherapy, and ipilimumab in patients with unresectable or metastatic melanoma after anti-PD-1 therapy},
  author={Taiki Isei and Kenji Yokota and Hisashi Uhara and Yasuhiro Fujisawa and Toshinao Takenouchi and Yutaka Kiyohara and Uchi Hiroshi and Hiroshi Saruta and Hironobu Ihn and Takashi Inozume and Daisuke Watanabe and Akihiko Takahashi and Satoshi Fukushima and Masahiro Tanaka and Naoya Yamazaki},
  year={2018}
}
Of 28 pts enrolled and treated as of the data cut-off 31 Aug 2018: The median age was 67 yrs (range: 31 to 81) and 43% pts were male. Disease stage was 7.1% IIIB, 28.6% IIIC and 64.3% IV. The most common subtype was 39.3% acral lentiginous and 21.4% mucosal melanoma. All pts were received prior therapies: 89.3% PD-1 monotherapy, 11% DTIC and 7% DAVFeron (DTIC, ACNU, Vincristine, and intradermal Interferon beta). 21.4% had ≥G3 C-REV-related AEs; adrenal insufficiency, constipation, hepatic… CONTINUE READING